EyePoint DURAVYU Lost 63%: How to Read a Post-Hoc Rescue

EyePoint Pharmaceuticals (EYPT) closed August 20 at $5.40, down 63% from the $14.75 it traded at the Friday before its LUGANO Phase 3 readout. Roughly $800 million of market value evaporated in one session. The reason is simple: DURAVYU, EyePoint’s 6-month sustained-release eye insert for wet age-related macular degeneration, missed the primary endpoint of its first registrational trial, and the company tried to rescue the read with an ad hoc analysis. Investors should treat that rescue as a warning, not a lifeline.

What LUGANO Actually Showed

The Phase 3 LUGANO trial (NCT06668064) was the first of two identical registrational trials for DURAVYU (vorolanib intravitreal insert, a sustained-release pan-VEGF/PDGFR tyrosine kinase inhibitor) in wet AMD. The primary endpoint was non-inferiority in average best-corrected visual acuity (BCVA) change versus on-label aflibercept at Weeks 52 and 56. DURAVYU missed it in the full dataset.

The company’s answer was an ad hoc analysis that excluded a 4% asymmetric cohort: 9 of 211 patients who lost at least 15 letters of vision for reasons unrelated to wet AMD. After dropping those nine patients, DURAVYU was non-inferior to aflibercept with a nominal p-value of 0.0096. The problem is that zero patients in the aflibercept control arm lost 15 or more letters for reasons unrelated to wet AMD. The exclusion was asymmetric by definition, and it flipped a failed endpoint into a passing one.

That is not the same as meeting the endpoint. Meeting the endpoint means the prespecified analysis in the prespecified population hits the bar. A post-hoc exclusion of nine patients who happened to be in the treatment arm is the sponsor negotiating with its own data. The FDA does not approve drugs on post-hoc analyses of a missed primary endpoint.

The Secondaries Are Real, and They Still Matter

None of that erases what DURAVYU’s secondary endpoints actually showed, because those point to the real value proposition. The whole pitch for a 6-month insert is treatment burden reduction, and on that score the data was strong. DURAVYU cut treatment burden by 42% (p<0.0001), and 76% of patients were supplement-free through Week 32. Among the 54% of DURAVYU eyes that were supplement-free through Week 56, central subfield thickness differed from aflibercept by just 3 microns, meaning the eyes that stayed quiet really stayed quiet.

Those numbers are why this story is not over. Wet AMD is treated with injections every 8 to 12 weeks for aflibercept, and every 16 weeks at best for Vabysmo, which still means a patient makes six to eight trips to the clinic a year for the rest of their life. A 6-month insert means two visits a year. The patient and system burden of that cadence is the single biggest unmet need in retinal disease, and a drug that keeps three quarters of patients injection-free for eight months would have a real commercial slot even in a crowded market. The vision endpoint is the regulatory gate, but the durability endpoint is the commercial thesis.

The Salvage Path: LUCIA

Everything now hinges on LUCIA, the second identical registrational trial, with topline data expected in Q4 2026 and a potential NDA in the first half of 2027. The bull case is that the 9-patient asymmetric cohort was bad luck, not a signal, and that LUCIA will not repeat it. If LUCIA hits non-inferiority on the prespecified analysis, DURAVYU is back on track.

The bear case is that the same confounding could recur, because the trial design is identical. The two trials are not independent tests of different hypotheses; they are two rolls of the same dice. A miss in LUCIA ends the wet AMD program, and DURAVYU’s remaining value collapses to its diabetic macular edema program, which is earlier and unproven.

That DME program is the forgotten asset in this story. EyePoint positions DURAVYU as the only tyrosine kinase inhibitor in development for diabetic macular edema, a market roughly the size of wet AMD with the same injection-burden problem. DME is a separate indication with its own trials, so a wet AMD failure does not automatically kill it. But it is years behind, and a company that just missed its lead indication’s primary endpoint does not get the benefit of the doubt on a second indication.

The Competitive Picture

The wet AMD market is a fortress of entrenched incumbents. Regeneron’s Eylea and Eylea HD hold roughly 35% of the market, and Roche’s Vabysmo is the growth engine; analysts project Vabysmo plus Eylea HD will generate a combined $13.2 billion by 2030. The overall AMD drug market runs from about $11 billion today toward $28 billion by 2033.

Into that field, every challenger is selling the same thing: fewer injections. Roche’s Susvimo is a refillable implant for continuous anti-VEGF delivery, with a Susvimo CHMP approval path in Europe. REGENXBIO is running two suravec Phase 3 trials aiming to replace injections entirely. Outlook Therapeutics’ Lytenava, approved for wet AMD, is a biosimilar-grade aflibercept chasing the value end of the market. DURAVYU’s differentiation is the 6-month cadence, which is longer than Susvimo’s refill interval and does not depend on a gene therapy’s one-time durability bet. That differentiation survives the LUGANO miss, but it now has to prove itself all over again in LUCIA.

Valuation

At $5.40, EyePoint carries a $543 million market cap against $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027. That is an enterprise value of roughly $363 million. Before the readout, at $14.75, the market cap was around $1.3 billion.

In other words, the market has already written DURAVYU’s wet AMD opportunity down to roughly zero and is now pricing the company as cash plus a cheap option on LUCIA and the DME program. The runway is a real asset: $180 million funds the company past the LUCIA readout, so there is no imminent dilution overhang.

Risks

The defining risk is binary: LUCIA. A second primary-endpoint miss sends the stock toward cash value, around $2 to $3, and probably lower once the market prices in the remaining burn.

Even a positive LUCIA carries regulatory risk. A filing built on one positive and one missed trial, with a post-hoc rescue on the books, invites a longer review and a narrower label.

The field is crowded too. Even a successful DURAVYU launch has to dislodge Eylea HD and Vabysmo, which have a decade of payer and physician relationships.

Verdict

This is a binary, not an investment. EyePoint at $5.40 is not a value entry, and the post-hoc rescue is not evidence of efficacy. The realistic read is a small, capped speculative position for traders who believe the 9-patient cohort was genuine bad luck rather than a signal. The asymmetry is real: if LUCIA hits, the stock re-rates toward $8 to $12 on the durability story; if it misses, it falls toward $2 to $3. Size it at 1% to 2% of a biotech portfolio, expect to lose it, and do not average down into a binary you cannot verify until Q4 2026.

There is a larger lesson here, and it recurs across the sector. When a company misses a prespecified primary endpoint and immediately publishes an ad hoc analysis that rescues it, the correct default is to discount the rescue heavily. The prespecified analysis is the only one that counts with the FDA, and a post-hoc pivot is a signal that the sponsor is negotiating with data it did not expect to see. You saw the same dynamic with a missed primary endpoint followed by a secondary-endpoint filing, and the correct response is identical: treat it as option value, not as a thesis. The durability data in LUGANO is real, but it will have to be proven again in a clean trial before it is worth anything.